News
News

The latest updates from AFAR.

Board member in the News: Thomas Rando’s insights at New Yorker TechFest in Digital Journal

Oct 23
2017

Board member in the News: Thomas Rando’s insights at New Yorker TechFest in Digital Journal View MoreBACK

On October 17, 2017, Digital Journal spotlighted perspectives shared by Board Member and 1999 Paul Beeson Career Development Scholar and a 2008 Glenn/AFAR Breakthroughs in Gerontology Award winner Thomas Rando, MD, PhD at the recent New Yorker TechFest.

The article, “Is aging a disease that can be cured?” shares insights from Dr. Rando on how the biological processes of aging drive major age-related diseases and the promise of biomedical research to target aging, noting:

While there’s no consensus among experts about whether aging is a disease at all, there’s no question that aging can make people more susceptible to diseases. “So if we can target aging we may be able to target these diseases,” Rando said.

The article also references the TAME (Targeting Aging with Metformin) Trial led by AFAR Deputy Scientific Director Nir Barzilai, MD.

Read the full article here.


 

Thomas A. Rando, MD, PhD, is the Principal Investigator of the Thomas Rando Lab at Stanford University, where he is also the Director of the Glenn Center for the Biology of Aging, Deputy Director of the Stanford Center on Longevity, and a Professor in the Department of Neurology and Neurological Sciences.

 





View MoreBACK TO TOP